Relfydess (RelabotulinumtoxinA): A Provider’s Clinical Guide
Why Relfydess Matters for Aesthetic Practices
Relfydess (relabotulinumtoxinA) is one of the first high‑profile ready‑to‑use liquid botulinum toxin type A formulations to enter the aesthetic market. It combines a complex‑free molecule with a fixed‑concentration liquid presentation and Phase 3 data suggesting rapid onset and sustained clinical improvement for glabellar lines and lateral canthal lines, with many patients maintaining effect around six months.
Key results have been shared in IMCAS 2025 Phase IIIb data, a glabellar lines Phase 3 trial, and the READY‑2 lateral canthal lines study.
For providers already offering Botox Cosmetic, Dysport, Xeomin, Jeuveau, and Daxxify, Relfydess introduces tangible practice questions: how to handle new unit math, how a fixed‑concentration liquid fits existing techniques, and when a 5–6‑month toxin is an asset versus a liability. This guide focuses on those clinical and operational decisions rather than headline claims.
What Is Relfydess (RelabotulinumtoxinA)?
Relfydess is a botulinum toxin type A1 neuromodulator supplied as a ready‑to‑use, complex‑free liquid solution for injection. Detailed information is available in the Galderma EU approval announcement, the UK Summary of Product Characteristics (SmPC), and regional prescribing documents.
Key formulation features:
- Fixed concentration of 10 units per 0.1 mL (100 units/mL), as outlined in the SmPC, the Australian Product Information, and the Spanish product leaflet.
- Ready‑to‑use” presentation, with no reconstitution required, emphasized in the UK SmPC, the Swedish SmPC, and clinical publications like the READY‑2 trial.
- Single‑patient, single‑session use: each vial is intended for one patient and one treatment session, with any remaining solution discarded, as noted in the patient leaflet and Spanish prescribing information.
- Product‑specific potency units that are not interchangeable with units of other botulinum toxin type A preparations, as clearly stated in the SmPC and patient information.
Current Indications and Regulatory Status
As of early 2026:
- Relfydess is approved in multiple international markets for temporary improvement of moderate‑to‑severe glabellar lines and lateral canthal lines (crow’s feet) in adults when the severity of these lines has an important psychological impact, based on the EU positive decision and regional product information.
- In the United States, the FDA has accepted Galderma’s Biologics License Application resubmission for relabotulinumtoxinA for glabellar lines and crow’s feet; it remains investigational pending formal approval, as noted in the FDA acceptance announcement, Practical Dermatology, and LiVDerm.
Always check the latest local prescribing information and regulatory updates for your region.
Who Is (and Isn’t) an Ideal Candidate?
With a potentially longer‑duration neuromodulator, patient selection matters as much as product choice.
Good Candidates for Longer‑Duration, Ready‑to‑Use Toxins
- Patients who reliably feel they “wear off too fast” on standard 3–4‑month neuromodulators despite appropriate dosing and technique.
- Time‑poor patients (frequent travelers, executives, busy parents) who value fewer visits and are comfortable with a convenience‑ or longevity‑based premium.
- High‑compliance, stable‑goals patients whose aesthetic preferences are unlikely to change dramatically over the next 6–12 months.
Situations for a More Cautious Approach
- Toxin‑naïve patients: if they dislike the look or experience heaviness, long duration becomes a problem rather than a feature.
- Patients in transition (planned major weight loss, pregnancy, new media‑facing roles) who may want shorter “commitment” windows.
- Patients with a history of atypical duration or adverse events on other toxins, where familiarity and rapid adjustability may matter more than maximum longevity.
The Clinical Evidence: What the Trials Show
Phase 3 and Phase IIIb Program
RelabotulinumtoxinA has been evaluated in a series of Phase 3 trials and a long‑term safety program, summarized in Galderma’s ASDS 2024 READY‑4 release, the READY‑4 article, and IMCAS 2025 RELAX data.
Key points:
- In glabellar lines, a Phase 3 trial showed statistically significant and clinically meaningful improvement versus placebo, with many patients maintaining a one‑ or two‑grade reduction on severity scales at six months (glabellar Phase 3 publication).
- In lateral canthal lines, the READY‑2 trial demonstrated significant improvement and durable effect, with onset over the first few days for most patients and many maintaining response around six months (PubMed abstract, full text).
- READY‑4 long‑term data show a safety profile consistent with other BoNT‑A products over repeated cycles (ASDS 2024 summary, READY‑4 coverage).
- Phase IIIb RELAX data suggest that a single treatment can maintain high response rates beyond six months in many glabellar patients (IMCAS 2025 update).
Onset and Duration: Probability, Not Promises
Trials and early real‑world reports indicate that some patients see effects as early as Day 1, with a substantial proportion showing clear improvement within several days, as noted in the READY‑2 study and Derm Digest coverage.
For duration, many patients maintain clinically meaningful improvement around six months in Phase 3 and Phase IIIb datasets (glabellar trial, lateral canthal lines study, READY‑4), but individual duration varies.
In consults, framing this as a distribution helps: “Many patients notice improvement within a few days, and a significant number still see benefit around six months, but timing and longevity vary from person to person.”
Complex‑Free Formulation and Immunogenicity
Relfydess is complex‑free, lacking the larger accessory proteins present in some BoNT‑A products. Reviews such as “Complexing Protein‑Free Botulinum Neurotoxin A Formulations” and broader analyses of botulinum toxin immunogenicity discuss how antigenic load, dose, and treatment interval influence neutralizing antibody development.
At aesthetic doses, it is reasonable to describe Relfydess as complex‑free with a safety profile comparable to other modern neuromodulators, while avoiding absolute claims that it prevents antibody formation or secondary non‑response.
Formulation, Precision, and the Fixed Concentration
The ready‑to‑use 10 units per 0.1 mL concentration removes dilution variability between injectors and simplifies preparation, as described in the SmPC and product characteristics.
Trade‑offs include less flexibility in using different dilutions to influence diffusion in sensitive areas. Practically, that argues for:
- Conservative first‑cycle dosing in frontalis and periocular regions.
- High‑precision 0.3–0.5 mL syringes to reliably deliver 0.1 mL (10‑unit) aliquots per injection site, consistent with the volumes in the SmPC and regional labeling.
Unit Non‑Interchangeability and “Unit Math”
Relfydess units are specific to this product and not interchangeable with units of other botulinum toxin type A formulations (SmPC, patient leaflet, Spanish information).
In multi‑toxin practices, this adds cognitive load. To reduce errors:
- Avoid informal “conversion charts” and treat Relfydess as its own dosing system based on label and trial patterns.
- Train staff to always document product, total dose, and per‑site dose in the correct units.
- Update EMR templates so that product, dose, and injection pattern are clearly captured for each toxin.
Storage, Shelf Life, and Use After Opening
According to the UK SmPC, Australian Product Information, and Spanish product details, Relfydess is stored refrigerated at 2°C–8°C in its carton, with an unopened shelf life of many months (jurisdiction‑specific).
Each vial is intended for a single patient in a single treatment session, with any remaining solution discarded (patient leaflet, Spanish information). Practices that routinely stretch reconstituted vials will need to adjust protocols and staff expectations for this single‑use model.
Relfydess Among Next‑Generation Neurotoxins
Relfydess joins other “next‑gen” neuromodulators such as Daxxify and liquid abobotulinumtoxinA. Trials like the Phase 3 liquid abobotulinumtoxinA glabellar study and a comparison of liquid versus powder abobotulinumtoxinA show that liquid formulations can deliver efficacy comparable to lyophilized products while changing workflow. Daxxify’s extended‑duration profile has been summarized in resources such as the ASPS comparison of Daxxify and Botox.
Rather than declaring a single “winner,” it’s more useful to decide:
- Which patients benefit from a longer‑duration or ready‑to‑use toxin.
- How product mix affects visit cadence, recall systems, and revenue.
- How to explain these choices clearly in consults without over‑promising.
Practice Management Considerations
Visit Cadence, Revenue, and Scheduling
Shifting some patients from 3–4‑month toxins to a 5–6‑month toxin can reduce yearly toxin visits. That may improve perceived value and convenience but also reduce spontaneous opportunities for add‑on services.
Questions to model internally:
- How will longer intervals affect per‑patient revenue and total visit volume?
- Can freed‑up time be used for new patients or higher‑value services?
- Do your recall and membership systems need to move away from a uniform “every 3 months” assumption?
Retention, Engagement, and “Missing Touchpoints”
Fewer toxin visits mean fewer automatic touchpoints. To maintain engagement:
- Add five extra minutes per Relfydess visit for planning, photography, and cross‑talk about skin or adjunct treatments.
- Schedule mid‑cycle nurse or virtual check‑ins focused on skincare and maintenance.
- Use email/SMS education to bridge the gap between in‑person visits.
Pricing, Consent, and Policies
Before launch, define:
- Where Relfydess sits price‑wise versus your other toxins (per‑unit, per‑area, or membership‑linked).
- A clear re‑treatment policy for patients who perceive earlier wear‑off than expected.
- Updated consent language for onset, duration ranges, and what happens if a patient is unhappy with a long‑lasting result.
Implementation: Pearls, Pitfalls, and Training
Clinical Pearls
- Treat first cycles as calibration: use label‑aligned dosing, schedule structured follow‑ups, and document onset/peak/fade patterns.
- Be conservative in high‑impact areas (frontalis, periocular) until you know how Relfydess behaves in your hands.
- Use precise syringes and technique to deliver consistent 0.1 mL volumes per injection point (SmPC guidance).
- Select ideal early adopters (time‑poor, well‑counseled patients) who are likely to perceive clear value from fewer visits.
Common Pitfalls
- Treating Relfydess units as interchangeable with other toxins, rather than following product‑specific dosing.
- Using opened vials across days or patients, contrary to typical single‑use guidance.
- Overselling “Day‑1 onset” or “6‑month results” based on consumer media like NewBeauty coverage or clinic blogs such as “Unlock smoother skin with Relfydess”.
- Launching without aligned consent language, retreat policies, and staff scripts, leading to inconsistent expectations and messaging.
Staff Training and Patient Communication
Before offering Relfydess, consider a focused internal session to cover:
- How it differs from your current neuromodulators (formulation, units, onset/duration, handling).
- One‑ or two‑sentence explanations for front desk and coordinators.
- How to respond when patients quote consumer press or trend pieces such as NewBeauty or neurotoxin trend articles.
Training, Certification, and Staying Current
Safe adoption of any new neuromodulator depends more on a provider’s foundation in anatomy, dosing, and complication management than on the specific brand. As more long‑duration and liquid toxins come to market, structured education becomes even more important.
For hands‑on training in Botox and other neuromodulators, as well as broader injectable best practices and practice‑building guidance, you can explore the IAPAM’s Botox and injectable training programs.
Bottom line: Relfydess is a promising addition to the neuromodulator portfolio, offering a complex‑free, ready‑to‑use formulation with strong onset and durability data. Evaluating where it fits in your practice means matching its strengths and trade‑offs to the right patients, pricing, and workflows—while grounding every decision in evidence rather than hype.
Download Your Free Botox Best Practices Guide
Discover proven techniques and industry insights to elevate your aesthetic practice. This comprehensive ebook covers essential protocols, patient safety, and advanced injection strategies used by top practitioners.
